Levostar Biotech

Executive Summary

Levostar Biotech is a privately held Chinese biotechnology company that leverages its proprietary mRNA synthesis, targeted lipid nanoparticle (tLNP) delivery, and in vivo functional validation platforms to develop next-generation cell and gene therapies, with a primary focus on in vivo CAR-T. Founded in 2020 and based in Suzhou, the company operates at the platform stage, offering end-to-end services from DNA design to in vivo characterization. Its integrated mRNA-LNP engineering approach aims to streamline the development of therapies across oncology, immunology, and infectious diseases, positioning it as a potential enabler of more accessible and scalable CAR-T treatments.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership announcement for in vivo CAR-T platform50% success